Geron Corporation rose 1.39% in after-hours trading, with the company reporting inducement grants under Nasdaq Listing Rules. The grants, which include stock options and restricted stock units, were made to eleven newly hired employees as an inducement material to their acceptance of employment with Geron. The company is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies.
Comments
No comments yet